Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrase inhibitor-containing ART in acute HIV infection
ChiCTR1800015005Phase 4Recruiting
- Sponsor
- NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dolutegravir, tenofovir disoproxil fumarate, lamivudine, efavirenz and lopinavir + ritonavir in Seroconversion Syndrome (2 arms), sponsored by NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital. Primary endpoints: HIV viral load and CD4 T-cell count. Started Jan 2018; status: recruiting.
02
Drugs
dolutegravirtenofovir disoproxil fumaratelamivudineefavirenzlopinavir + ritonavir
03
Conditions
Seroconversion Syndrome
Beyond the preview
Go deeper on ChiCTR1800015005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015005.